| 1 |
35460941 | Low doses of niclosamide and quinacrine combination yields synergistic effect in melanoma via activating autophagy-mediated p53-dependent apoptosis. | 2022 Jul |
4 |
| 2 |
31562955 | Repurposing quinacrine for treatment-refractory cancer. | 2021 Jan |
4 |
| 3 |
29386219 | A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers. | 2018 Apr 15 |
6 |
| 4 |
29545477 | Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in p53-Negative Malignant Cancers. | 2018 Jun |
1 |
| 5 |
21544805 | Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. | 2012 Apr 1 |
1 |
| 6 |
23193914 | Quinacrine-mediated autophagy and apoptosis in colon cancer cells is through a p53- and p21-dependent mechanism. | 2012 |
2 |
| 7 |
21518868 | FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB. | 2011 May 10 |
1 |
| 8 |
21569639 | Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. | 2011 May 15 |
1 |
| 9 |
21725212 | Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. | 2011 Aug 1 |
3 |
| 10 |
21725213 | Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. | 2011 Aug 1 |
1 |
| 11 |
19137016 | 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. | 2009 Feb 26 |
1 |
| 12 |
18006756 | Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. | 2007 Nov 15 |
8 |
| 13 |
16177561 | Acridine derivatives activate p53 and induce tumor cell death through Bax. | 2005 Aug |
2 |
| 14 |
16287968 | Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. | 2005 Nov 29 |
2 |
| 15 |
12082016 | High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. | 2002 Jun |
1 |